GFAP and Alzheimer disease: In future work, adding in other promising plasma measures, such as plasma p-tau217 [16], which may be more sensitive to earlier AD pathology than p-tau181, and glial fibrillary acidic protein may further increase the predictive power of the combined biomarker.